Somatostatin receptor 1 and/or 4 selective agonists and antagonists

A compound of Formula II

• or a pharmaceutically acceptable salt or ester thereof,
• wherein
• Q is
• 1) H,
• 2) aryl or
• 3) heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 4 substituents selected from Ra, or
• 4) a group of formula
• wherein R4 is
• 1) H,
• 2) (C1-C6)alkyl,
• 3) (C2-C6)alkenyl,
• 4) (C2-C6)alkynyl,
• 5) Cy,
• 6) Cy-(C1-C6)alkyl,
• 7) Cy-(C2-C6)alkenyl or
• 8) Cy-(C2-C6)alkynyl, wherein alkyl, alkenyl, alkynyl and Cy are unsubstituted or substituted with 1 or 2 substituents selected from Rd,
• R5 is
• 1) H,
• 2) (C1-C6)alkyl,
• 3) (C2-C6)alkenyl,
• 4) (C2-C6)alkynyl,
• 5) aryl,
• 6) aryl-(C1-C6)alkyl,
• 7) heteroaryl or
• 8) heteroaryl-(C1-C6)alkyl, wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 4 substituents selected from Rd, or
• R4 and R5 together with the atom to which they are attached form a 3- to 8-membered ring containing 0 to 2 heteroatoms selected from the group consisting of N, O and S, wherein said ring is unsubstituted or substituted with 1 to 3 substituents selected from Rd, or said ring is fused to aryl or heteroaryl, either of which is unsubstituted or substituted with 1 to 3 substituents selected from Rd;
• A is
• 1) H,
• 2) (C1-C6)alkyl or
• 3) (C3-C5)cycloalkyl;
• B is independently
• 1) H,
• 2) halogen or
• 3) (C1-C6)alkyl, or
• symbols B together form a double or triple bond between the atoms to which they are attached;
• R1 is
• 1) H,
• 2) (C1-C6)alkyl or
• 3) (C3-C7)cycloalkyl;
• R2 is independently
• 1) H,
• 2) (C1-C6)alkyl,
• 3) (C2-C6)alkenyl,
• 4) (C2-C6)alkynyl,
• 5) (C3-C7)cycloalkyl or
• 6) (C3-C7)cycloalkyl(C1-C6)alkyl, or
• symbols R2 together with the nitrogen to which they are attached form a saturated 5- to 7-membered ring containing 1 or 2 heteroatoms selected from the group consisting of N, O and S;
• R3 is
• 1) H,
• 2) (C1-C6)alkyl,
• 3) (C2-C6)alkenyl,
• 4) (C2-C6)alkynyl or
• 5) (C3-C7)cycloalkyl;
• R6 is independently
• 1) H,
• 2) halogen,
• 3) —NO2,
• 4) —NRbRb,
• 5) —CN,
• 6) —ORb,
• 7) —SRb,
• 8) —C(O)Rb,
• 9) (C1-C6)alkyl,
• 10) (C2-C6)alkenyl,
• 11) (C2-C6)alkynyl,
• 12) (C3-C7)cycloalkyl or
• 13) —CF3;
• Ra is independently
• 1) H,
• 2) halogen,
• 3) —ORb,
• 4) (C1-C6)alkyl or
• 5) —CF3;
• Rb is independently
• 1) hydrogen,
• 2) (C1-C6)alkyl,
• 3) (C2-C6)alkenyl,
• 4) (C2-C6)alkynyl,
• 5) Cy or
• 6) Cy-(C1-C4)alkyl;
• Rd is independently
• 1) a group selected from Rc,
• 2) (C1-C6)alkyl,
• 3) (C2-C6)alkenyl,
• 4) (C2-C6)alkynyl,
• 5) aryl,
• 6) aryl-(C1-C6)alkyl,
• 7) heteroaryl-(C1-C6)alkyl,
• 8) (C3-C7)cycloalkyl or
• 9) heterocyclyl, wherein alkyl, alkenyl, alkynyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 4 substituents independently selected from Rc;
• Rc is independently
• 1) a group selected from Ra,
• 2) —NO2,
• 3) —SRb,
• 4) —NRbRb,
• 5) —CN or
• 6) —NRbC(O)Rb;
• Cy is cycloalkyl, heterocyclyl, aryl or heteroaryl;
• t is an integer from 0 to 3;
• n is the integer 1 or 2;
• X is a bond or C(R6);
• and
• L is C(R6), S or N.